World-leading tissue proteomic services provider, ProCan Technologies Limited has today launched the TargetQuantTM Antibody-Drug Conjugate (ADC) Panel at BIO2025 in Boston, USA. The panel is designed to support the development of ADCs across a wide range of cancers.
Leveraging the capabilities and intellectual property developed within the ProCan program at Children’s Medical Research Institute in Sydney, Australia, ProCan Technologies’ vision is to enhance and maximise the outcomes of oncology research and clinical trials globally.
With the global ADC market projected to reach $34.7 billion by 2030, the efficacy of an ADC drug, and therefore its overall success, depends on the answer to one critically important question – Is the target present in the patient's tumour?
Most ADCs rely on antibodies binding to cell surface proteins, making protein expression the key determinant of the drug interaction and therefore efficacy. Understanding this protein expression through direct, quantitative measurement is crucial.
Guided by its in-house team of seven board-certified medical oncologists, ProCan is using mass spectrometry (MS)-based proteomics to quantify protein abundance, including cell surface targets, across thousands of real-world, clinically annotated tumour samples – 32,000 samples from more than 100 cancer types processed to date on a single platform.
Building on this data and knowledge, ProCan Technologies has now developed the TargetQuantTM ADC Panel to directly quantify ADC target expression in FFPE or frozen tumour samples
The panel currently quantifies16 ADC target proteins in a single assay. This will be updated and expanded as the number of ADCs going through clinical trials and obtaining regulatory approval evolves. Overall, the TargetQuantTM ADC Panel offers the ability to validate the presence of ADC targets in relevant cancer types, quantitate the target, identify potential off-target effects and screen multiple candidate targets in a single assay. This will all assist with the development of biomarkers for trial design and patient stratification.
ProCan co-founder Professor Roger Reddel said ‘The TargetQuantTM ADC Panel will assist the acceleration of oncology clinical trials through rapid, scalable insights for target selection, trial design, and market access strategies’.
ProCan Technologies are participating in the bio-partnering at BIO2025 in Boston this week and are available to meet with companies interested in discussing the panel further.